In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
Page
Malcolm G P
MG
Basilea Pharmaceutica International Ltd., Basel CH-4005, Switzerland. Malcolm.page@basilea.com
Dantier
Clothilde
C
Desarbre
Eric
E
D000150:Acinetobacter / Q000187:drug effects; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D024901:Drug Resistance, Multiple, Bacterial / Q000235:genetics; D004755:Enterobacteriaceae / Q000187:drug effects; D004926:Escherichia coli / Q000187:drug effects; D029968:Escherichia coli Proteins / Q000037:antagonists & inhibitors; D006090:Gram-Negative Bacteria / Q000187:drug effects* / Q000235:genetics / Q000378:metabolism; D006801:Humans; D008826:Microbial Sensitivity Tests; D008997:Monobactams / Q000494:pharmacology*; D009154:Mutation; D046915:Penicillin-Binding Proteins / Q000037:antagonists & inhibitors; D010641:Phenotype; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D017262:Siderophores / Q000494:pharmacology*; D013844:Thiazoles / Q000494:pharmacology*; D047090:beta-Lactams / Q000494:pharmacology*
D000900:Anti-Bacterial Agents; C552042:BAL 30072; D029968:Escherichia coli Proteins; D008997:Monobactams; D046915:Penicillin-Binding Proteins; D017262:Siderophores; D013844:Thiazoles; D047090:beta-Lactams